$XBIO Xenetics Bio on strong watch for breakout

******HOT STOCK ON THE WATCHLIST FOR THEY COMING DAYS, PURE SPECULATION AND RUMOR PICK, UNUSUAL BUY VOLUME AND PRICE SPIKE.**********************


COMPANY PROFILE
Xenetic Biosciences, Inc. engages in the discovery, research, and development of next generation biologic drugs and novel orphan oncology therapeutics. Its lead investigational product candidate is oncology therapeutic XBIO-101 (sodium cridanimod), which focuses on the treatment of progesterone resistant endometrial cancer. It also offers proprietary drug development platform, PolyXen, which enables next-generation biologic drugs by improving their half-life and other pharmacological properties. The company was founded on August 9, 2011 and is headquartered in Framingham, MA.